DOI:
10.1055/s-00050348
Indian Journal of Medical and Paediatric Oncology
LinksClose Window
References
Tolaney SM, Wardley AM, Zambelli S. et al
Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial.
Lancet Oncol 2020;
21 (06) 763-775
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.